Arbutus Biopharma Ownership
| ABUS Stock | USD 3.31 0.11 3.44% |
Shares in Circulation | First Issued 2007-06-30 | Previous Quarter 188 M | Current Value 189 M | Avarage Shares Outstanding 57 M | Quarterly Volatility 54.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Arbutus |
Arbutus Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.43. Arbutus Biopharma Corp had not issued any dividends in recent years. The entity had 1:5 split on the 4th of November 2010. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus infection, SARS-CoV-2, and other coronaviruses in the United States. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Arbutus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people. For more info on Arbutus Biopharma Corp please contact William Collier at 267 469 0914 or go to https://www.arbutusbio.com.Besides selling stocks to institutional investors, Arbutus Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Arbutus Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Arbutus Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Arbutus Biopharma Quarterly Liabilities And Stockholders Equity |
|
Arbutus Biopharma Insider Trades History
About 22.0% of Arbutus Biopharma Corp are currently held by insiders. Unlike Arbutus Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Arbutus Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Arbutus Biopharma's insider trades
Arbutus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arbutus Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arbutus Biopharma Corp backward and forwards among themselves. Arbutus Biopharma's institutional investor refers to the entity that pools money to purchase Arbutus Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-12-31 | 1.4 M | Northern Trust Corp | 2024-12-31 | 1.3 M | Fourworld Capital Management Llc | 2024-12-31 | 1.2 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | Hudson Bay Capital Management Lp | 2024-12-31 | 1.1 M | Woodline Partners Lp | 2024-12-31 | 971.6 K | Jpmorgan Chase & Co | 2024-12-31 | 896.3 K | Saba Capital Management, Lp | 2024-12-31 | 888 K | Corbin Capital Partners Lp | 2024-12-31 | 682.5 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 22.6 M | Whitefort Capital Management, Lp. | 2024-12-31 | 13.2 M |
Arbutus Biopharma Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arbutus Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arbutus Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arbutus Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arbutus Biopharma Outstanding Bonds
Arbutus Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arbutus Biopharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arbutus bonds can be classified according to their maturity, which is the date when Arbutus Biopharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Arbutus Biopharma Corporate Filings
F3 | 6th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of February 2025 Other Reports | ViewVerify | |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.